FLT3 and acute myeloid leukemia: Another FLT3-inhibitor, quizartinib (AC220), is currently investigated in a phase I/II trial in children with FLT3-mutated r/r AML in combination with re-induction chemotherapy and as single-agent maintenance therapy (NCT03793478).